Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study (Q58912037)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 June 2015

Language	Label	Description	Also known as
English	Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study	scientific article published on 12 June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

0 references

chronic neuropathic pain

0 references

neuropathic pain

0 references

pain management

0 references

1 reference

based on heuristic

inferred from title

Emilio Martin-Mola

3

object named as

Emilio Martin-Mola

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Ralf Baron

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Rudolf Likar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Lieven Kennes

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Matthias Müller

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Dietmar Falke

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Ilona Steigerwald

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Francisco J Blanco

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

publication date

12 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

580-599

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

The global burden of low back pain: estimates from the Global Burden of Disease 2010 study

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Modelling the prevalence and cost of back pain with neuropathic components in the general population

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Assessment and diagnosis of neuropathic pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Prevalence of chronic pain with neuropathic characteristics in the general population.

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Synergistic interaction between the two mechanisms of action of tapentadol in analgesia

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Points to consider on switching between superiority and non-inferiority

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Risk-benefit assessment of opioids in chronic noncancer pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: a review

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Neuropathic pain: a maladaptive response of the nervous system to damage

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1111/PAPR.12308

21 January 2018

Identifiers

10.1111/PAPR.12308

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26095455 AND SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58912037&oldid=2230486232"